Medicare Anti-VEGF Evaluation: TA Notes Safety Comparison Challenges For Avastin, Cost-Benefit Data

The Institute for Clinical and Economic Review conducted a technology assessment for anti-VEGF agents in diabetic macular edema for CMS in preparation for an upcoming MedCAC review.